Repertoire Immune Medicines struck a major partnership with Eli Lilly worth up to approximately $1.92 billion to develop tolerizing therapies for autoimmune diseases using Repertoire’s Decode platform. The deal includes an up‑front payment and tiered milestones plus royalties, adding Lilly to a roster of pharma partners that have backed Repertoire’s discovery engine. Repertoire said the pact expands external validation of its single‑cell, immune‑repertoire‑driven discovery approach that aims to generate tolerizing vaccines and antigen‑specific therapies. Lilly’s involvement signals continued big‑pharma appetite for platforms that can map immune specificity and translate it into targeted immunomodulators. The agreement highlights a broader trend of major pharmas licensing computationally driven immunology platforms to accelerate discovery in complex immune diseases, where conventional target nomination has struggled to deliver disease‑modifying therapies.